CEL-SCI CORPORATION Stock Issued During Period, Value, Employee Benefit Plan
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- CEL-SCI CORPORATION stock issued during period, value, employee benefit plan for the quarter ending 2026-06-30 was $60.56K, a 13.56% increase year-over-year.
- CEL-SCI CORPORATION stock issued during period, value, employee benefit plan for the quarter ending 2026-03-31 was $61.79K, a 14.31% increase year-over-year.
- CEL-SCI CORPORATION stock issued during period, value, employee benefit plan for the quarter ending 2025-12-31 was $57.26K, a 0.22% increase year-over-year.
- CEL-SCI CORPORATION stock issued during period, value, employee benefit plan for the quarter ending 2025-06-30 was $53.32K, a 11.97% decline year-over-year.
- CEL-SCI CORPORATION stock issued during period, value, employee benefit plan for fiscal 2025 was $218.32K, a 0.18% decline from fiscal 2024.
- CEL-SCI CORPORATION stock issued during period, value, employee benefit plan for fiscal 2024 was $218.72K, a 5.36% increase from fiscal 2023.
- CEL-SCI CORPORATION stock issued during period, value, employee benefit plan for fiscal 2023 was $207.59K, a 6.93% decline from fiscal 2022.
- CEL-SCI CORPORATION stock issued during period, value, employee benefit plan for fiscal 2022 was $223.04K, a 10.91% increase from fiscal 2021.
| Period end | Stock Issued During Period, Value, Employee Benefit Plan 3 month | Stock Issued During Period, Value, Employee Benefit Plan 12 month |
|---|---|---|
| 2026-06-30 | $60.56K 10-Q · filed 2026-08-14 | |
| 2026-03-31 | $61.79K 10-Q · filed 2026-08-14 | |
| 2025-12-31 | $57.26K 10-Q · filed 2026-08-14 | |
| 2025-09-30 | $218.32K 10-K · filed 2025-12-29 | |
| 2025-06-30 | $53.32K 10-Q · filed 2026-08-14 | |
| 2025-03-31 | $54.05K 10-Q · filed 2026-08-14 | |
| 2024-12-31 | $57.13K 10-Q · filed 2026-08-14 | |
| 2024-09-30 | $218.72K 10-K · filed 2025-12-29 | |
| 2024-06-30 | $60.58K 10-Q · filed 2025-08-14 | |
| 2024-03-31 | $53.48K 10-Q · filed 2025-08-14 | |
| 2023-12-31 | $48.91K 10-Q · filed 2025-08-14 | |
| 2023-09-30 | $207.59K 10-K · filed 2025-01-13 | |
| 2023-06-30 | $52.66K 10-Q · filed 2024-08-14 | |
| 2023-03-31 | $54.87K 10-Q · filed 2024-08-14 | |
| 2022-12-31 | $50.18K 10-Q · filed 2024-08-14 | |
| 2022-09-30 | $223.04K 10-K · filed 2023-12-21 | |
| 2022-06-30 | $57.21K 10-Q · filed 2023-08-10 | |
| 2022-03-31 | $57.52K 10-Q · filed 2023-08-10 | |
| 2021-12-31 | $52.55K 10-Q · filed 2023-08-10 | |
| 2021-09-30 | $201.10K 10-K · filed 2022-12-27 | |
| 2021-06-30 | $53.20K 10-Q · filed 2022-08-12 | |
| 2021-03-31 | $51.42K 10-Q · filed 2022-08-12 | |
| 2020-12-31 | $41.67K 10-Q · filed 2022-08-12 | |
| 2020-09-30 | $163.34K 10-K · filed 2021-12-21 | |
| 2020-06-30 | $42.90K 10-Q/A · filed 2020-12-31 | $158.18K derived: sum of 4 quarters · filed 2021-02-12 |
| 2020-03-31 | $38.96K 10-Q/A · filed 2020-12-31 | $151.65K derived: sum of 4 quarters · filed 2021-02-12 |
| 2019-12-31 | $40.94K 10-Q · filed 2021-02-12 | $149.57K derived: sum of 4 quarters · filed 2021-02-12 |
| 2019-09-30 | $35.39K derived: 10-K 12 month − 10-Q 9 month · filed 2020-12-29 | $143.88K 10-K · filed 2020-12-29 |
| 2019-06-30 | $36.36K 10-Q/A · filed 2020-12-31 | $144.50K derived: sum of 4 quarters · filed 2020-12-31 |
| 2019-03-31 | $36.88K 10-Q/A · filed 2020-12-31 | $144.81K derived: sum of 4 quarters · filed 2020-12-31 |
| 2018-12-31 | $35.24K 10-Q/A · filed 2020-12-31 | $144.45K derived: sum of 4 quarters · filed 2020-12-31 |
| 2018-09-30 | $36.02K derived: 10-K/A 12 month − 10-Q 9 month · filed 2019-12-23 | $145.09K 10-K/A · filed 2019-12-23 |
| 2018-06-30 | $36.67K 10-Q · filed 2019-08-14 | $145.90K derived: sum of 4 quarters · filed 2019-08-14 |
| 2018-03-31 | $36.52K 10-Q · filed 2019-08-14 | $147.28K derived: sum of 4 quarters · filed 2019-08-14 |
| 2017-12-31 | $35.88K 10-Q · filed 2019-08-14 | $148.82K derived: sum of 4 quarters · filed 2019-08-14 |
| 2017-09-30 | $36.83K derived: 10-K 12 month − 10-Q 9 month · filed 2018-12-19 | $151.31K 10-K · filed 2018-12-19 |
| 2017-06-30 | $38.06K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-08-14 | $396.75K derived: sum of 4 quarters · filed 2018-08-14 |
| 2017-03-31 | $38.05K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-05-15 | $320.14K derived: sum of 4 quarters · filed 2018-05-15 |
| 2016-12-31 | $38.37K 10-Q · filed 2018-02-12 | $240.94K derived: sum of 4 quarters · filed 2018-02-12 |
| 2016-09-30 | $282.26K derived: 10-K 12 month − 10-Q/A 9 month · filed 2017-12-29 | $161.57K 10-K · filed 2017-12-29 |
| 2016-06-30 | -$38.55K derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2017-12-11 | $168.02K derived: sum of 4 quarters · filed 2017-12-11 |
| 2016-03-31 | -$41.15K derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2017-12-11 | $164.15K derived: sum of 4 quarters · filed 2017-12-11 |
| 2015-12-31 | -$40.99K 10-Q/A · filed 2017-12-11 | $164.99K derived: sum of 4 quarters · filed 2017-12-11 |
| 2015-09-30 | $288.71K derived: 10-K/A 12 month − 10-Q 9 month · filed 2017-12-11 | $165.65K 10-K/A · filed 2017-12-11 |
| 2015-06-30 | -$42.42K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-08-09 | $148.34K derived: sum of 4 quarters · filed 2017-12-11 |
| 2015-03-31 | -$40.31K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-05-10 | $151.50K derived: sum of 4 quarters · filed 2017-12-11 |
| 2014-12-31 | -$40.34K 10-Q · filed 2016-02-09 | $152.98K derived: sum of 4 quarters · filed 2017-12-11 |
| 2014-09-30 | $271.40K derived: 10-K/A 12 month − 10-Q 9 month · filed 2017-12-11 | $155.43K 10-K/A · filed 2017-12-11 |
| 2014-06-30 | -$39.26K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-08-07 | |
| 2014-03-31 | -$38.82K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-05-08 | |
| 2013-12-31 | -$37.89K 10-Q · filed 2015-02-06 | |
| 2013-09-30 | $158.86K 10-K · filed 2015-12-11 | |
| 2012-09-30 | $154.52K 10-K · filed 2014-12-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |